These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8854933)

  • 1. [Scientific rationale for the replacement of an in vivo bioassay for protein drugs with a physico-chemical assay].
    Hayakawa T
    Eisei Shikenjo Hokoku; 1994; (112):202-3. PubMed ID: 8854933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the activity of clinical grade human growth hormone preparations by in vivo bioassay, in vitro cell proliferation assay and solid phase radioimmunoassay.
    Aston R; Whitaker AM; Baldwin AL; Holder AT
    Dev Biol Stand; 1986; 64():227-34. PubMed ID: 3792648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reduction of the number of animals used in the biological assay of insulin.
    Trethewey J; Baxter D; Fisher BV; Sabey GA; Webb FW
    Dev Biol Stand; 1986; 64():221-6. PubMed ID: 3539668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of chemical derivatization to clinical drug analysis.
    Sternson LA
    Xenobiotica; 1987 Mar; 17(3):385-96. PubMed ID: 3554788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of assay validation in specification development.
    Baffi RA
    Dev Biol Stand; 1997; 91():105-13. PubMed ID: 9413687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of therapeutic growth hormone preparations: report of an interlaboratory collaborative study on growth hormone assay methodologies.
    Bristow AF; Jeffcoate SL
    Biologicals; 1992 Sep; 20(3):221-31. PubMed ID: 1457107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study on preparation and activity of a novel recombinant human parathyroid hormone(1-34) analog with N-terminal Pro-Pro extension.
    Chunxiao W; Jingjing L; Yire X; Min D; Zhaohui W; Gaofu Q; Xiangchun S; Xuejun W; Jie W; Taiming L
    Regul Pept; 2007 Jun; 141(1-3):35-43. PubMed ID: 17300845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and problems in the replacement of in vivo pharmacopoeial bioassays for hormones.
    Bristow AF; Charton E
    Dev Biol (Basel); 2002; 111():79-88. PubMed ID: 12678227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
    Meager A; Das RG
    J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioassay of HGH: standardization of more economical assay designs.
    Bartolini P; Muramoto E
    Horm Metab Res; 1984 Nov; 16(11):614-5. PubMed ID: 6510893
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitative analysis of pharmacokinetic study samples by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS).
    Mück W
    Pharmazie; 1999 Sep; 54(9):639-44. PubMed ID: 10522267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy.
    Borget I; Laville I; Paci A; Michiels S; Mercier L; Desmaris RP; Bourget P
    Eur J Pharm Biopharm; 2006 Aug; 64(1):92-8. PubMed ID: 16750352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of bioassays for the characterisation and control of biological therapeutic products produced by biotechnology.
    Thorpe R; Wadhwa M; Mire-Sluis A
    Dev Biol Stand; 1997; 91():79-88. PubMed ID: 9413686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of N-palmitoylated human growth hormone by in situ liquid-liquid extraction and MALDI tandem mass spectrometry.
    Sachon E; Nielsen PF; Jensen ON
    J Mass Spectrom; 2007 Jun; 42(6):724-34. PubMed ID: 17428000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
    Bredehöft M; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of juvenile animal studies to determine the human effects and risks of environmental toxicants during postnatal developmental stages.
    Brent RL
    Birth Defects Res B Dev Reprod Toxicol; 2004 Oct; 71(5):303-20. PubMed ID: 15505806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical considerations in the development of protein purification processes.
    Anicetti V; Hancock WS
    Bioprocess Technol; 1994; 18():11-36. PubMed ID: 7764169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel preparative high-performance liquid chromatography with on-line molecular mass characterization.
    Edwards C; Liu J; Smith TJ; Brooke D; Hunter DJ; Organ A; Coffey P
    Rapid Commun Mass Spectrom; 2003; 17(18):2027-33. PubMed ID: 12955730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method.
    Lecároz C; Campanero MA; Gamazo C; Blanco-Prieto MJ
    J Antimicrob Chemother; 2006 Sep; 58(3):557-63. PubMed ID: 16787953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.